KBC Group NV Purchases 274,144 Shares of CVS Health Corporation $CVS

KBC Group NV lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 40.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 950,953 shares of the pharmacy operator’s stock after acquiring an additional 274,144 shares during the quarter. KBC Group NV’s holdings in CVS Health were worth $68,297,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp grew its stake in CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its stake in CVS Health by 2.9% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 725,189 shares of the pharmacy operator’s stock valued at $57,551,000 after buying an additional 20,217 shares during the period. Legal & General Group Plc boosted its holdings in shares of CVS Health by 0.3% during the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock worth $738,777,000 after buying an additional 31,249 shares in the last quarter. Deutsche Bank AG grew its position in shares of CVS Health by 28.4% during the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after buying an additional 1,031,998 shares during the period. Finally, Hussman Strategic Advisors Inc. bought a new stake in shares of CVS Health in the 4th quarter valued at $3,333,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE CVS opened at $107.49 on Tuesday. The company has a market cap of $137.15 billion, a P/E ratio of 47.35, a PEG ratio of 1.05 and a beta of 0.61. The company has a fifty day simple moving average of $99.28 and a 200 day simple moving average of $85.36. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $108.97.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is currently 117.18%.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CVS has been the topic of a number of research reports. UBS Group boosted their target price on shares of CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Sanford C. Bernstein raised their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Mizuho increased their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, Barclays raised their target price on CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.